Targeting inflammation in heart failure with histone deacetylase inhibitors

Molecular Medicine

Volumn 17, Issue 5-6, 2011, Pages 434-441

  McKinsey, Timothy A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; APICIDIN; DEOXYCORTICOSTERONE ACETATE; ENTINOSTAT; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MYOCYTE ENHANCER FACTOR 2; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; VORINOSTAT;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDITIS; DEACETYLATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ANALYSIS; ENZYME INHIBITION; EPIGENETICS; GENE FUNCTION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNOMODULATION; IN VIVO STUDY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; T CELL LYMPHOMA; TREATMENT DURATION;

ANIMALS; HEART FAILURE; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS;

EID: 79957964666     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00022     Document Type: Article

References (80)

1. Lloyd-Jones D, et al. (2009) Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 119:480-486.
2. Deswal A, et al. (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 103:2055-2059.
3. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323:236-241.
4. Rauchhaus M, et al. (2000) Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 102:3060-3067.
5. Bozkurt B, Mann DL, Deswal A. (2010) Biomark-ers of inflammation in heart failure. Heart Fail. Rev. 15:331-341.
6. Schindler R, Dinarello CA, Koch KM. (1995) An-giotensin-converting-enzyme inhibitors suppress synthesis of tumour necrosis factor and inter-leukin 1 by human peripheral blood mononu-clear cells. Cytokine. 7:526-533.
7. Abbate A, et al. (2008) Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 117:2670-2683.
8. Bujak M, et al. (2008) Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. Am. J. Pathol. 173:57-67.
9. Abbate A, et al. (2010) Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am. J. Cardiol. 105:1371-1377.
10. Bozkurt B, et al. (2001) Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 103:1044-1047.
11. Deswal A, et al. (1999) Safety and efficacy of a soluble P75 tumor necrosis factor receptor (En-brel, etanercept) in patients with advanced heart failure. Circulation. 99:3224-3226.
12. Mann DL, et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 109:1594-1602.
13. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 107:3133-3140.
14. Burchfield JS, et al. (2010) The cytoprotective effects of tumor necrosis factor are conveyed through tumor necrosis factor receptor-associated factor 2 in the heart. Circ. Heart Fail. 3:157-164.
15. Yang XJ, Seto E. (2008) Lysine acetylation: codi-fied crosstalk with other posttranslational modifications. Mol. Cell. 31:449-461.
16. Gregoretti IV, Lee YM, Goodson HV. (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J. Mol. Biol. 338:17-31.
17. McKinsey TA, Zhang CL, Olson EN. (2002) MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem. Sci. 27:40-47.
18. Devereux RB, et al. (2004) Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 292:2350-2356.
19. Gardin JM, Lauer MS. (2004) Left ventricular hypertrophy: the next treatable, silent killer? JAMA. 292:2396-2398.
20. Han A, et al. (2003) Sequence-specific recruitment of transcriptional co-repressor Cabin1 by my-ocyte enhancer factor-2. Nature. 422:730-734.
21. Han A, He J, Wu Y, Liu JO, Chen L. (2005) Mechanism of recruitment of class II histone deacety-lases by myocyte enhancer factor-2. J. Mol. Biol. 345:91-102.
22. Backs J, Song K, Bezprozvannaya S, Chang S, Olson EN. (2006) CaM kinase II selectively signals to histone deacetylase 4 during cardiomy-ocyte hypertrophy. J. Clin. Invest. 116:1853-1864.
23. Bush E, et al. (2004) A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 101:2870-2875.
24. Vega RB, et al. (2004) Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol. Cell. Biol. 24:8374-8385.
25. Zhang CL, et al. (2002) Class II histone deacety-lases act as signal-responsive repressors of cardiac hypertrophy. Cell. 110:479-488.
26. Chang S, et al. (2004) Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol. Cell. Biol. 24:8467-8476.
27. Antos CL, et al. (2003) Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J. Biol. Chem. 278:28930-28937.
28. Bradner JE, et al. (2010) Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6:238-243.
29. Heltweg B, et al. (2004) Subtype selective substrates for histone deacetylases. J. Med. Chem. 47:5235-5243.
30. Marks PA, Breslow R. (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25:84-90.
31. Kook H, et al. (2003) Cardiac hypertrophy and hi-stone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J. Clin. Invest. 112:863-871.
32. Kee HJ, et al. (2006) Inhibition of histone deacety-lation blocks cardiac hypertrophy induced by an-giotensin II infusion and aortic banding. Circulation. 113:51-59.
33. Liu F, et al. (2008) Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibro-sis in cardiac hypertrophy independent of an-giotensin. J. Mol. Cell Cardiol. 45:715-723.
34. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. (2004) Histone deacetylase is a target of val-proic acid-mediated cellular differentiation. Cancer Res. 64:1079-1086.
35. Matalon S, et al. (2010) The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and mono-cytes and is superior to valproic acid for latent HIV-1 expression in vitro. J. Acquir. Immune Defic. Syndr. 54:1-9.
36. Terbach N, Williams RS. (2009) Structure-function studies for the panacea, valproic acid. Biochem. Soc. Trans. 37:1126-1132.
37. Kong Y, et al. (2006) Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation. 113:2579-2588.
38. Granger A, et al. (2008) Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J. 22:3549-3560.
39. Lee TM, Lin MS, Chang NC. (2007) Inhibition of histone deacetylase on ventricular remodeling in infarcted rats. Am. J. Physiol. Heart Circ. Physiol. 293:H968-H977.
40. Zhang LX, et al. (2010) Targeted deletion of NF-kappa B p50 diminishes the cardioprotection of histone deacetylase inhibition. Am. J. Physiol. Heart Circ. Physiol. 298:H2154-H2163.
41. Zhao TC, Cheng G, Zhang LX, Tseng YT, Pad-bury JF. (2007) Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury. Cardiovasc. Res. 76:473-481.
42. Cardinale J P, et al. (2010) HDAC inhibition attenuates inflammatory, hypertrophic, and hypertensive responses in spontaneously hypertensive rats. Hypertension. 56:437-444.
43. Iyer A, et al. (2010) Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br. J. Pharmacol. 159:1408-1417.
44. Cho YK, et al. (2010) Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ. J. 74:760-770.
45. Voelkel NF, et al. (2006) Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 114:1883-1891.
46. Kee HJ, et al. (2008) Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy. Circ. Res. 103:1259-1269.
47. Trivedi CM, et al. (2007) Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat. Med. 13:324-331.
48. Haberland M, Montgomery RL, Olson EN. (2009) The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10:32-42.
49. Montgomery RL, et al. (2007) Histone deacety-lases 1 and 2 redundantly regulate cardiac mor- phogenesis, growth, and contractility. Genes. Dev. 21:1790-1802.
50. Gallo P, et al. (2008) Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc. Res. 80:416-424.
51. Bush EW, McKinsey TA. (2010) Protein acetyla-tion in the cardiorenal axis: the promise of his-tone deacetylase inhibitors. Circ. Res. 106:272-284.
52. Tao R, et al. (2007) Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat. Med 13:1299-1307.
53. Wang L, de Zoeten EF, Greene MI, Hancock WW. (2009) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regu latory T cells. Nat. Rev. Drug. Discov. 8:969-981.
54. Littman DR, Rudensky AY. (2010) Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 140:845-858.
55. Saouaf SJ, et al. (2009) Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 87:99-104.
56. de Zoeten EF, Wang L, Sai H, Dillmann WH, Hancock WW. (2010) Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology. 138:583-594.
57. Tang TT, et al. (2010) Defective circulating CD4CD25+Foxp3+CD127(low) regulatory T-cells in patients with chronic heart failure. Cell Physiol. Biochem. 25:451-458.
58. Kvakan H, et al. (2009) Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation. 119:2904-2912.
59. Kee HJ, Kook H. (2009) Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy. J. Mol. Cell Car-diol. 47:770-780.
60. Liao X, et al. (2010) Kruppel-like factor 4 regulates pressure-induced cardiac hypertrophy. J. Mol. Cell Cardiol. 49:334-338.
61. Gupta MP, Samant SA, Smith SH, Shroff SG. (2008) HDAC4 and PCAF bind to cardiac sarcom- eres and play a role in regulating myofilament contractile activity. J. Biol. Chem. 283:10135-10146.
62. Brown RD, Ambler SK, Mitchell MD, Long CS. (2005) The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annu. Rev. Pharmacol. Toxicol. 45:657-687.
63. Porter KE, Turner NA. (2009) Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Ther. 123:255-278.
64. Barter MJ, et al. (2010) HDAC-mediated control of ERK- and PI3K-dependent TGF-beta-induced extracellular matrix-regulating genes. Matrix Biol. 29:602-612.
65. Yoshikawa M, Hishikawa K, Idei M, Fujita T. (2010) Trichostatin a prevents TGF-beta1-induced apoptosis by inhibiting ERK activation in human renal tubular epithelial cells. Eur. J. Pharmacol. 642:28-36.
66. Guo W, Shan B, Klingsberg RC, Qin X, Lasky JA. (2009) Abrogation of TGF-beta1-induced fibrob- last-myofibroblast differentiation by histone deacetylase inhibition. Am. J. Physiol. Lung Cell Mol. Physiol. 297:L864-L870.
67. Zeisberg EM, et al. (2007) Endothelial-to-mes-enchymal transition contributes to cardiac fibro-sis. Nat. Med. 13:952-961.
68. Weiskirchen R, et al. (2009) BMP-7 as antagonist of organ fibrosis. Front Biosci. 14:4992-5012.
69. Widyantoro B, et al. (2010) Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothe-lial-to-mesenchymal transition. Circulation. 121:2407-2418.
70. Peinado H, Ballestar E, Esteller M, Cano A. (2004) Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/HDAC2 complex. Mol. Cell. Biol. 24:306-319.
71. Borlaug BA, Kass DA. (2006) Mechanisms of di-astolic dysfunction in heart failure. Trends Cardio-vasc. Med. 16:273-279.
72. Borlaug BA. (2009) Treatment of heart failure with preserved ejection fraction. Curr. Treat. Options Cardiovasc. Med. 11:79-87.
73. Liang K P, et al. (2010) Increased prevalence of di-astolic dysfunction in rheumatoid arthritis. Ann. Rheum. Dis. 69:1665-1670.
74. Marks PA. (2010) The clinical development of hi-stone deacetylase inhibitors as targeted anti-cancer drugs. Expert Opin. Investig. Drugs. 19:1049-1066.
75. Galli M, et al. (2010) A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Ann. Hematol. 89:185-190.
76. Giles F, et al. (2006) A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 12:4628-4635.
77. Klimek VM, et al. (2008) Tolerability, pharmaco-dynamics, and pharmacokinetics studies of dep-sipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodys-plastic syndromes. Clin. Cancer Res. 14:826-832.
78. O'Connor OA, et al. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoy-lanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24:166-173.
79. Matsuoka H, et al. (2007) Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur. J. Pharmacol. 571:88-96.
80. Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452-1458.